Initial post marketing experience with lacosamide in adult patients with epilepsy.
The outcomes of adult epilepsy patients prescribed lacosamide for additional seizure control. Responders were defined as having at least a 50% decrease in seizure frequency Sixty-seven patients were evaluated. Forty-six out of 67 patients (69%) were responders. Twelve of 14 patients not taking sodium channel-acting AEDs were responders (86%) and 34/53 patients taking sodium channel-acting AEDs were responders (64%) (difference not significant).
Hofstra North Shore-LIJ School of Medicine, Cushing Neuroscience Institutes, Brain and Spine Specialists, North Shore-Long Island Jewish Health System, 270-05 76th Avenue, New Hyde Park, NY 11040, United States. charden@nshs.edu
Cynthia L
CL
Harden
Aaron
A
Cohn
Merredith
M
Lowe
Enrique
E
Serrano
D000081:Acetamides / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000927:Anticonvulsants / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D000078334:Lacosamide; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D016896:Treatment Outcome; D055815:Young Adult
D000081:Acetamides; D000927:Anticonvulsants; D000078334:Lacosamide